Implants and methods for treating inflammation-mediated conditions of the eye
Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.
1. An implant for treating an inflammation-mediated condition of an eye, the implant comprising dexamethasone and a bioerodible copolymer, the implant structured to be placed in the vitreous of the eye and deliver dexamethasone to the vitreous in an amount sufficient to reach an in vivo concentration equivalent to at least 0.05 μg/mL dexamethasone within about 48 hours and to maintain an in vivo concentration equivalent to at least 0.03 μg/mL dexamethasone for at least about three weeks.